Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SSKN 
STRATA Skin Sciences Inc (SSKN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SSKN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.92% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.76M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 2 | Beta 0.66 | 52 Weeks Range 1.61 - 3.52 | Updated Date 08/29/2025 |
52 Weeks Range 1.61 - 3.52 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-13 | When - | Estimate 0.01 | Actual -0.6 |
Profitability
Profit Margin -35.13% | Operating Margin (TTM) -29.02% |
Management Effectiveness
Return on Assets (TTM) -11.13% | Return on Equity (TTM) -235.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18854456 | Price to Sales(TTM) 0.27 |
Enterprise Value 18854456 | Price to Sales(TTM) 0.27 | ||
Enterprise Value to Revenue 0.57 | Enterprise Value to EBITDA -7008.83 | Shares Outstanding 4171160 | Shares Floating 1172430 |
Shares Outstanding 4171160 | Shares Floating 1172430 | ||
Percent Insiders 4.02 | Percent Institutions 63.54 |
Upturn AI SWOT
STRATA Skin Sciences Inc
Company Overview
History and Background
STRATA Skin Sciences, formerly known as MELA Sciences, was founded in 1989. It initially focused on developing and commercializing the MelaFind system for early melanoma detection. Over time, the company has expanded its product portfolio to include other dermatology devices, reflecting an evolution towards a broader range of skin treatment solutions.
Core Business Areas
- Dermatology Devices: STRATA Skin Sciences focuses on developing, commercializing, and marketing medical devices used in the treatment of dermatological conditions. Their core products leverage light-based therapies.
Leadership and Structure
The leadership team consists of experienced executives in the medical device industry. The organizational structure is typical for a publicly traded company, with a board of directors overseeing management.
Top Products and Market Share
Key Offerings
- XTRAC Laser System: An excimer laser system used for the treatment of psoriasis, vitiligo, and eczema. Market share data is not readily available. Competitors include PhotoMedex (acquired by an Italian pharma company), and other laser device manufacturers.
- Pharos EX-308 Excimer Laser: Another excimer laser system with similar applications to XTRAC. Market share data is not readily available. Competitors include PhotoMedex (acquired by an Italian pharma company), and other laser device manufacturers.
Market Dynamics
Industry Overview
The dermatology device market is driven by an aging population, increasing prevalence of skin conditions, and growing demand for non-invasive treatments. Technological advancements and rising aesthetic awareness also contribute to market growth.
Positioning
STRATA Skin Sciences occupies a niche position within the dermatology device market, focusing on light-based therapies for specific skin conditions. Its competitive advantage lies in its established product portfolio and direct sales force.
Total Addressable Market (TAM)
The global dermatology devices market is projected to reach billions of dollars. STRATA Skin Sciences is positioned to capture a portion of this TAM through its focused product offerings.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Direct sales force
- Focus on specific dermatological conditions
- Proprietary technology
Weaknesses
- Limited product diversification
- Smaller market capitalization compared to competitors
- Dependence on light-based therapies
- Past financial performance
Opportunities
- Expanding applications of existing products
- Geographic expansion
- Development of new dermatology devices
- Strategic partnerships
Threats
- Intense competition
- Technological advancements by competitors
- Regulatory changes
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- CUTI
- LBRX
- ISRG
Competitive Landscape
STRATA Skin Sciences faces competition from larger medical device companies with greater resources. Its competitive advantage lies in its focus on specific dermatological applications, while its disadvantages include smaller market capitalization and limited product diversification.
Major Acquisitions
Ra Medical Systems
- Year: 2023
- Acquisition Price (USD millions): 4.4
- Strategic Rationale: The company acquired Ra Medical Systems, which added DABRA excimer laser system to its product range
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require a review of past financial performance.
Future Projections: Future projections are best obtained from analyst reports, which are typically subscription-based services.
Recent Initiatives: Recent strategic initiatives require monitoring company press releases and investor relations updates.
Summary
STRATA Skin Sciences operates in a competitive dermatology device market, facing challenges from larger players. The company's focus on light-based therapies and direct sales force are strengths, but limited product diversification and past financial performance require attention. Recent acquisitions like Ra Medical Systems represent strategic moves to enhance product offerings. Continued innovation and expansion are vital for sustained growth in a dynamic market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market data and share information might be delayed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STRATA Skin Sciences Inc
Exchange NASDAQ | Headquaters Horsham, PA, United States | ||
IPO Launch date 2005-10-28 | President, CEO & Vice-Chairman Dr. Dolev Rafaeli Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 106 | |
Full time employees 106 | |||
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, and other skin conditions; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.